NatureU® Now Has Three Clinical Studies Publicly Registered on ClinicalTrials.gov as 56-Day PQQ Skin-Aging Study (NCT07571629) Joins Two Previously Published Peer-Reviewed Trials

Read original · https://www.globenewswire.com/news-release/2026/06/05/3307666/0/en/natureu-now-has-three-clinical-studies-publicly-registered-on-clinicaltrials-gov-as-56-day-pqq-skin-aging-study-nct07571629-joins-two-previously-published-peer-reviewed-trials.html

Top 2 movers · tap to explore

What matters in this story

NatureU's exploratory study of BeautyU Caps showed a 46.7% decrease in crow's-feet wrinkles and a 58.7% increase in skin hydration after 56 days. — Positive efficacy data for a new product can drive sales and brand value, though the study is exploratory and not yet peer-reviewed.

+0.30

OmniSolutions Laboratory Holdings Limited has now registered three separate clinical studies on ClinicalTrials.gov, including trials for sleep and weight management. — Expanding a portfolio of clinically backed products increases the company's scientific credibility and competitive positioning in the nutraceutical market.

+0.20

The latest BeautyU skin-aging study results have been released as a preprint and have not yet undergone formal peer review. — The lack of peer review introduces a level of scientific risk and uncertainty regarding the validity of the reported results.

-0.10

NatureU® Now Has Three Clinical Studies Publicly Registered on ClinicalTrials.gov as 56-Day PQQ Skin-Aging Study (NCT07571629) Joins Two Previously Published Peer-Reviewed Trials

What matters in this story

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS

NatureU® Now Has Three Clinical Studies Publicly Registered on ClinicalTrials.gov as 56-Day PQQ Skin-Aging Study (NCT07571629) Joins Two Previously Published Peer-Reviewed Trials

What matters in this story

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial

AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC

NatureU® Now Has Three Clinical Studies Publicly Registered on ClinicalTrials.gov as 56-Day PQQ Skin-Aging Study (NCT07571629) Joins Two Previously Published Peer-Reviewed Trials

What matters in this story

Next reads from the same story arc

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS

NatureU® Now Has Three Clinical Studies Publicly Registered on ClinicalTrials.gov as 56-Day PQQ Skin-Aging Study (NCT07571629) Joins Two Previously Published Peer-Reviewed Trials

What matters in this story

Next reads from the same story arc

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial

AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC